Nurix Therapeutics

Nurix Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2009. The company focuses on discovering, developing, and commercializing small molecule therapies that target E3 ubiquitin ligases, which play a crucial role in the protein degradation process within cells. Nurix utilizes its proprietary DEL-AI discovery engine, combining DNA Encoded Libraries, automated chemistry, and machine learning to create innovative degrader-based medicines. The company primarily targets immune-mediated diseases, hematologic cancers, and immuno-oncology. Its clinical pipeline includes drug candidates like NX-2127 and DeTIL-0255, which are currently in trials for various cancers and autoimmune conditions. Nurix has formed strategic collaborations with major pharmaceutical companies such as Gilead Sciences, Sanofi, Pfizer, and Bristol Myers Squibb, enhancing its capabilities in drug discovery and development. Nurix Therapeutics is publicly traded on NASDAQ under the ticker NRIX.